Clinical trial NCT00041041 (phase 2, status: completed)
Conditions: primary peritoneal cavity cancer, recurrent ovarian epithelial cancer
ICD codes: C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818, H18.523, H18.521, H18.522, H18.529
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

               -  Recurrent or persistent disease

          -  At least 1 unidimensionally measurable target lesion

               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

               -  Tumors within a previously irradiated field considered nontarget lesions

          -  At least one prior platinum-based chemotherapy regimen (containing carboplatin,
             cisplatin, or another organoplatinum compound) for primary disease required

               -  Initial treatment may include high-dose, consolidation, or extended therapy

               -  Initial treatment-free interval less than 12 months for patients who received
                  only 1 prior platinum-based regimen

               -  Initial treatment-free interval of more than 12 months allowed provided disease
                  progression has occurred within 12 months after retreatment with a second-line
                  platinum-based regimen

          -  Ineligible for a higher priority GOG protocol (e.g., any active phase III GOG protocol
             for the same patient population)

          -  Performance status - GOG 0-2 (if patient has received one prior treatment regimen)

          -  Performance status - GOG 0-1 (if patient has received two prior treatment regimens)

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGOT/SGPT no greater than 2.5 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  Creatinine no greater than 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after study participation

          -  No active infection requiring antibiotics

          -  No greater than grade 1 sensory and motor neuropathy

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No signs or symptoms of bowel dysfunction

          -  At least 3 weeks since prior immunologic therapy directed at the malignant tumor

          -  No concurrent biologic therapy or immunotherapy for the malignant tumor

          -  Recovered from prior chemotherapy

          -  No prior noncytotoxic chemotherapy for persistent or recurrent disease

          -  One additional cytotoxic regimen for persistent or recurrent disease allowed

          -  No concurrent chemotherapy for the malignant tumor

          -  At least 1 week since prior hormonal therapy directed at the malignant tumor

          -  No concurrent therapeutic corticosteroids

          -  No concurrent anticancer hormonal therapy

          -  Concurrent hormone replacement therapy allowed

          -  Recovered from prior radiotherapy

          -  No prior radiotherapy to more than 25% of marrow-bearing areas

          -  No concurrent anticancer radiotherapy

          -  Recovered from recent prior surgery

          -  At least 3 weeks since other prior therapies directed at the malignant tumor

          -  No prior imatinib mesylate

          -  No prior anticancer therapy that would preclude study participation

          -  No concurrent therapeutic anticoagulation with warfarin

          -  No other concurrent investigational drugs

          -  No concurrent amifostine or other protective reagents